Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would Macfarlane leaving Alfred Health have anything to do with the start date of p2/3? According to it, he left in June 2016.
Taken from his linkedin: HERE
Director/Associate Professor, Aged Psychiatry
Company NameCaulfield Hospital (Alfred Health)
Dates Employed2008 – Jun 2016 Employment Duration8 yrs 6 mos
As the longest-serving Director of Aged Psychiatry in this position since the creation of the Department in 1994, I ran a 40-EFT aged psychiatry service in south-east Melbourne, comprising a 15-bed acute inpatient unit, a community case management service and a liaison psychiatry service to some 300 aged care, rehabilitation and acquired brain injury beds.
My time was split between administration, teaching, working as the acute inpatient consultant on the ward, and running a clinical trials/research unit that deals primarily with industry-sponsored trials of potential disease-modifying agents for Alzheimer's disease.
I think I read that each share would have an option to exercise their right to buy a share at a said price.
Think someone could break down all the rights this would give so the common person could understand what the shareholder rights would actually do for us?
Yes, which could be the reason Missling is on the conference tour trying to get the name out.
In this crooked game where BP livelihoods could vanish, anything is possible because we are a threat to them. To think they aren't circling us from above like vultures is foolish. We already survived one playbook thrown at us and here we still stand.
A 1:4 to get on the Nasdaq yes. A 1:32 would look a bit suspicious no?
One could get the idea that Biogen got the results and are impressed with it,but isn't offering enough to make Missling say yes.
I had to read what you wrote and I like the way they twisted your words around. I understand what you meant. Reviewed by peers and peer reviewed is two totally different meanings.
Bryostatin might have peer reviewed articles but their data will be reviewed and ridiculed by peers on how 3 months of an Alzheimer's trial can hold any water.
Nice post,
Yes things could have been a lot worse, but his finance skills shined and didn't allow us to dilute when everyone expected him to.
The worse they can say is " no placebo, everyone knows they taking a drug" what they don't say is they know they taking a drug, and 99% of the time the trial fails.
It's been pretty bearable this last few days, meaning we should be climbing steps again. Hopefully that elusive mountain peak soon.
Its still an OTC. Didn't up list yet.
Blueberry's, if taken for 12 weeks just like how Bryostatin will have been, shows promise that it too can make a meaningful, positive effect against alzheimers. Blueberry juice did better in helping improve memory over the placebo in a blind study. See below for the 3 month data readout.
"This study indicated that wild blueberry juice supplementation for 12 weeks improved memory function in older adults with early memory decline. To our knowledge, this is the first human trial assessing the potential benefit of blueberry supplementation on neurocognitive function in older adults with increased risk for dementia."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850944/
So how would you feel about a trial that would run for ONLY 3 months?
Because you know, there IS this one company that believes 3 months is enough of a p2 to see the results before moving on to a p3.
Looks like you got your publicity question answered today.
These two tweets 15 hours ago puts the urgency into reality
https://twitter.com/bio1x1
#Alzheimer’s disease costs Japan 14.5 trillion yen in direct and indirect costs, and 600-800 billion dollars globally
In 2035, 1/3 of the Japanese population will reach the age of 65. #BIOASIA17
After doing the foolish mistake of investing in APHQF when the $1M pr came out they invested in Tetra, and recommending to a friend to buy GRPOF when it was $.18 I closed my position and opened one here for the long haul. Hope to be a positive contributor here just as I try to be at my other long hold of AVXL.
Well, to be fair I emailed IR and showed them a way their website can be accessed via anything that they uploaded. I showed them how there's was and how it should block all other pages if it wasn't a direct page. Glad they listened and fixed it because one could have monitored that page and viewed it before they made the link public. Come to think of it, it probably was like that back in 2015 when we had the infamous pr and naked shorting right after.
Do I need to provide a screen of my email and their reply for everyone to believe?
Yes, I know of that one also because its the day April options expire.
Bottom line, we need something to advance. Either a p2 to start or p2/3 Alzheimer's.
Im done responding today as I ran out of posts. Have a great one everyone
Exactly. Which is why IMO, they are shooting for a buyout vs going the distance. 3 month trial is a pretty safe point to stop the trial. Limit the risk and move on to p3 fast before p2 shows the ever familiar decline. Wait, the company is RUSHING the trial for the patients.......
With Silverman Chairman of the Board, I highly doubt that.
LOL, this graph and that explanation has been tried before
Iroquois Master Fund is a little scary.Iroquois Master fund is a Cayman Islands exempted limited company.Read This
Joshua Silverman Co-Founder, Managing Partner, and Managing Member, Iroquois Capital Management L.L.C.
Iroquois seems to buy large stakes in companies, then recommend their selection be added to the board, which they then use their new stake to vote for.
Whats the address of Neurotrope? Taken directly from their site.
Corporate Address
Neurotrope BioScience,
205 East 42nd Street, 16th Floor
New York, NY 10017
Phone: (973) 242-0005
Whats the address of Iroquois Capital Management L.L.C.? Thats right here
205 East 42nd Street
16th Floor
New York, NY 10017
United States
So who did Iroquois recommend to have on Neurotrope board?HERE
Also part of the settlement is the resignation of Paul E. Freiman and Jay M. Haft from the company’s board of directors, effective immediately. The board has appointed Joshua Silverman chairman of the board and Kenneth J. Gorelick to the board, also effective immediately.
So we have Iroquois's Joshua Silverman, co-founder of Iroquois capital management llc, receiving the chairman of the board,
and Gorelick not only to the board, but also Chief Medical Director.
I'm starting to see your concern Xena. Chief Medical Director could be nothing more than a puppet for Silverman
Which could be the reason why we see Alzheimers trial only at 3 months.
Quote:
When Anavex releases their data,IMO, it WILL be positive.
The definition of "positive" in these here parts is different than what I'm used to.
Yet, here we are arguing about placeholders?
Because corporate actions tell us a lot about motivations.
Dare I argue though that the low n count received something no other Alzheimer patient ever received, IMPROVEMENT and/or STABILIZATION.
uh, no
When Anavex releases their data,IMO, it WILL be positive. The same nay-sayers will say its meaningless because the n is too low. Dare I argue though that the low n count received something no other Alzheimer patient ever received, IMPROVEMENT and/or STABILIZATION.
Yet, here we are arguing about placeholders?
Look at Xena sticky about 6 presentations
Blanchette Rockefeller Neurosciences Institute IS Neurosciences Research Ventures, Inc., at least thats what I get from the SEC filing:
https://www.sec.gov/Archives/edgar/data/1618058/000119312516655870/0001193125-16-655870-index.htm
Except now BRNI is now Cognitive Research Enterprises.
BRNI owns 10M shares pre-rs. They would gain the most, as they are the ones that licensed Bryostatin-1 to Neurotrope. Just thought I'd throw that out there.
They simply removed the abstract link from the schedule:
A03.f. Drug Development, Clinical Trials: Neuroprotective and mitochondrial compounds
The direct link still works, so more than likely they had to remove the old stuff that was on there, and come the day that the company PR the news, the link will then be filled with the newest data.
I like that the Dr. went to Asia for a conference, where 28% of all attendees attend it at that region. Only one higher is the North America one in San Diego, which is 31%.
Then theres adpd in Austria, which 46% of all attendees are from Western Europe. Good exposure for those outside of the U.S. to the company.
I guess it was a bad thing that AF said positive things about NTRP. Good thing there's tutes already holding a significant amount of shares already.
Dr. Missling at Asiabio thanks to matt krebs on twitter for taking the pic for us
@ the Anavax presentation. Interesting! Chk out more info on our @BioCentury Platform here: https://t.co/Uj6oXLliAJ pic.twitter.com/QfqkXnhrYZ
— matt krebs (@krebs_matt) March 14, 2017
Yea, one of the lucky few the last 2 years. Still keep an eye on it though
Same here. It's only 715 pm here in Hawaii . I'll keep an eye out for the next couple hours
I think they are trying to rush through the trial so they can sell to the highest bidder. No other reason why a p2 trial for Alzheimer's would only last for 3 months. Saying it's to help patients live longer sounds like bs IMO. I'm out of my little position for NTRP before the uplisting happens. Lol
I just had a starter amount.
Sounds like a colorful board member at the other place. Now saying mild ALZ isn't ALZ at all. If that so happened to be the case, I'm sure other clinical trials that selected mild to moderate patients would have seen SOME positive reactions. But nope. AVXL is going somewhere, just that it didn't need a 32:1 rs to get there. We shall see which drug looks more promising in the next year.
Would it be considered a good or bad thing to have AF tweeting positives for NTRP?
https://www.thestreet.com/story/14040641/1/neurotrope-shares-soar-as-alzheimer-s-drug-trial-lottery-ticket-call-nears.html
seeking alpha article
http://seekingalpha.com/article/4054680-alzheimers-disease-next
Alzheimer's Disease: What's Next?
Mar. 13, 2017 4:02 PM ET| About: Anavex Life Sciences Corp. (AVXL), Includes: NTRPD
Lane Simonian
Lane Simonian
Biotech, alternative energy
(233 followers)
Summary
Several drugs and approaches to Alzheimer's disease are based on factors other than amyloid and tau.
Of these, ones which have antioxidant effects may be the most effective.
Combination therapies which inhibit oxidant production and remove oxidants may produce the best results.
Although anti-amyloid and anti-tau clinical trials are still ongoing, the recent trial failures with each make it time to consider the alternatives.
One alternative is to increase or decrease the activation of receptors involved in memory. This includes a 5-HT6 serotonin receptor antagonist (Axovant (NYSE:AXON) RVT-101), a mixed muscarinic receptor agonist and antagonist (Anavex (NASDAQ:AVXL) 2-73), a CB2 receptor agonist (NeuroTherapia NTRX-07), and an insulin receptor agonist (inhaled insulin). The problem with this approach is that all these receptors are already damaged in Alzheimer's disease.
The damage done to them by oxidation and nitration have to be reversed first before agonists will work and using antagonists makes no sense as the receptors are not working in the first place. Unless these drugs have a different mechanism of action (which is the case for Anavex 2-73 and may be the case for NeuroTherapia NTRX-07) drugs targeting these receptors have little chance of success.
Another approach is to increase energy production in the brain. Accera AC-1204 by producing ketones provides the brain with another source of energy. But while AC-1204 showed promise in a Phase 2 trial it was not successful in a recent Phase 3 trial. It is possible that ketones in the long run are an inadequate substitute for declining levels of glucose in the brain.
Yet another strategy is to reduce inflammation. The damage done to DNA, lipid peroxidation, and the release of glutamate all lead to inflammation in Alzheimer's disease. However over time, the brain's main immune cells - microglia - are damaged in Alzheimer's disease (study). So while certain anti-inflammatory drugs may be useful during the early stages of the disease, their effect may decrease as the disease progresses.
Stem cell therapy is yet another approach. Part of the problem in Alzheimer's disease is that neurons die and they are not replaced. Stem cells would at least temporarily address this problem, but may not increase levels of neurotransmitters or improve neurotransmissions themselves.
This largely leaves one alternative - antioxidants. Several antioxidants have been ineffective in the treatment of Alzheimer's disease. Some are not effective scavengers of hydrogen peroxide and peroxynitrite - the chief oxidants in Alzheimer's disease (hydrogen peroxide early on). Others do not reach the brain in high enough concentrations (curcumin and ketones, for instance, in current formulations).
Two drugs under consideration have antioxidant effects. Bryostatin by Neurotrope (OTCQB:NTRPD) downregulates protein kinase C alpha and protein kinase C alpha is the linchpin in the initial production of inflammation and oxidation in Alzheimer's disease (bryostatin's effect, protein kinase C alpha). However, due to damage to upstream receptors in most people with Alzheimer's disease, protein kinase C alpha activity decreases as the disease progresses (study). So it is not likely that bryostatin can be used to help most people at least not past a certain stage.
Anavex 2-73 is the second drug with antioxidant properties being tested for Alzheimer's disease. Explaining its role requires a brief explanation of disease progression.
Protein kinase C alpha initially triggers NMDA receptor activation and the subsequent production of peroxynitrite which leads to the death of neurons. After this there is a cycle: peroxynitrite (in part by limiting the transport of glutamate) leads to perpetual NMDA receptor activation and the perpetual NMDA receptor activation leads to the accelerated production of peroxynitrite. Inhibiting NMDA receptor activation, inhibiting intermediate molecules that lead to the production of peroxynitrite, and/or scavenging peroxynitrite is likely the key to treating Alzheimer's disease (Alzheimer's strategies).
The drug Anavex 2-73 is part of the answer as it inhibits the intermediate enzyme neuronal nitric oxide synthase (mechanism of action). And if Anavex 2-73 is combined with effective peroxynitrite scavengers then there may be an even more positive effect on cognition and activities of daily living than either used alone. The one suggestion at this point is combining Anavex 2-73 with low doses of THC but perhaps an even better combination is with different forms of panax ginseng (THC, heat processed ginseng, Korean red ginseng).
Without oxidative stress, there is no Alzheimer's disease. Unfortunately, for everyone at this point (I suppose with the possible exception of Anavex shareholders), there are few drug companies focused primarily on this target.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Enthusiasm is great, but remember that at least 3 of them are about or mentions A-371 and its potential.
Still helps with putting Anavex in the minds of those not familiar with us.
Lets not forget who the inventor of AF710B(A-371)is. None other than Fisher himself.
http://www.anavex.com/anavex-appoints-dr-abraham-fisher-to-scientific-advisory-board/
All this makes for an interesting April options expiration day, since expiration is April 21, day of Anavex round table.
HETEROMERIZATION OF M1 MUSCARINC/SIGMA1 RECEPTORS AS A UNIQUE THERAPEUTIC TARGET IN AD AND RELATED CNS DISEASES
6:45pm - 7:00pm
Thu, Mar 30
Another session about AF710B no speaker info yet though. Seems like a push for A-371 is occurring this conference.
TBA TBA: Invited Speaker
HETEROMERIZATION OF M1 MUSCARINC/SIGMA1 RECEPTORS AS A UNIQUE THERAPEUTIC TARGET IN AD AND RELATED CNS DISEASES
http://cmoffice.kenes.com/ADPD17/CM.NET.WebUI/CM.NET.WEBUI.scpr/SCPRfunctiondetail.aspx?confID=05000000-0000-0000-0000-000000000195&sesID=05000000-0000-0000-0000-000000041983&absID=07000000-0000-0000-0000-000000565552
Attila it shows up as 25.750% on my fidelity
Its not all insiders SS.
Add up the directors shares(5,114,421) with the tutes shares(8,595,312). You can get the tute shares as of last quarter at fintel.
Divide them all by the os, which is given in the proxy statement as
41376061
Its how the 33% was figured.